Gilead submits hepatitis C drug sofosbuvir for FDA approval

04/9/2013 | American City Business Journals · RTT News

Gilead Sciences filed a new drug application with the FDA for sofosbuvir, an oral nucleotide analogue, to treat chronic hepatitis C virus infection. The firm seeks to use sofosbuvir in combination with existing treatments ribavirin and pegylated interferon in treatment-naive patients with genotype 1, 4, 5 and 6 infection. The drug is expected to be approved by year's end or early next year.

View Full Article in:

American City Business Journals · RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations